In:
PLOS ONE, Public Library of Science (PLoS), Vol. 18, No. 2 ( 2023-2-1), p. e0279830-
Kurzfassung:
Hmong men in Minnesota exhibit a high prevalence of gout and hyperuricemia. Although evidence of vitamin C’s effectiveness as a treatment for gout is mixed, analysis of therapeutic benefit based on an individual’s multiomic signature may identify predictive markers of treatment success. Objectives The primary objective of the H mong M icrobiome AN d G out, O besity, Vitamin C (HMANGO-C) study was to assess the effectiveness of vitamin C on serum urate in Hmong adults with and without gout/hyperuricemia. The secondary objectives were to assess if 1) vitamin C impacts the taxonomic and functional patterns of microbiota; 2) taxonomic and functional patterns of microbiota impact vitamin C’s urate-lowering effects; 3) genetic variations impact vitamin C’s urate-lowering effects; 4) differential microbial biomarkers exist for patients with or without gout; and 5) there is an association between obesity, gut microbiota and gout/hyperuricemia. Methods This prospective open-labelled clinical trial was guided by community-based participatory research principles and conducted under research safety restrictions for SARS-CoV-2. We aimed to enroll a convenient sample of 180 Hmong adults (120 with gout/hyperuricemia and 60 without gout/hyperuricemia) who provided medical, demographic, dietary and anthropometric information. Participants took vitamin C 500mg twice daily for 8 weeks and provided pre-and post- samples of blood and urine for urate measurements as well as stool samples for gut microbiome. Salivary DNA was also collected for genetic markers relevant to uric acid disposition. Expected results We expected to quantify the impact of vitamin C on serum urate in Hmong adults with and without gout/hyperuricemia. The outcome will enhance our understanding of how gut microbiome and genomic variants impact the urate-lowering of vitamin C and associations between obesity, gut microbiota and gout/hyperuricemia. Ultimately, findings may improve our understanding of the causes and potential interventions that could be used to address health disparities in the prevalence and management of gout in this underserved population. Trial registration ClinicalTrials.gov NCT04938024 (first posted: 06/24/2021).
Materialart:
Online-Ressource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0279830
DOI:
10.1371/journal.pone.0279830.g001
DOI:
10.1371/journal.pone.0279830.s001
DOI:
10.1371/journal.pone.0279830.s002
DOI:
10.1371/journal.pone.0279830.s003
DOI:
10.1371/journal.pone.0279830.s004
DOI:
10.1371/journal.pone.0279830.s005
DOI:
10.1371/journal.pone.0279830.s006
DOI:
10.1371/journal.pone.0279830.s007
DOI:
10.1371/journal.pone.0279830.s008
DOI:
10.1371/journal.pone.0279830.s009
DOI:
10.1371/journal.pone.0279830.s010
DOI:
10.1371/journal.pone.0279830.s011
DOI:
10.1371/journal.pone.0279830.s012
DOI:
10.1371/journal.pone.0279830.r001
DOI:
10.1371/journal.pone.0279830.r002
DOI:
10.1371/journal.pone.0279830.r003
DOI:
10.1371/journal.pone.0279830.r004
DOI:
10.1371/journal.pone.0279830.r005
DOI:
10.1371/journal.pone.0279830.r006
Sprache:
Englisch
Verlag:
Public Library of Science (PLoS)
Publikationsdatum:
2023
ZDB Id:
2267670-3
Permalink